Beijing, China, 24 November 2025
Gauthier Philippart (CEO Trasis), Xiaoping HU & Jessie YU (CTO & CEO of Beijing PET Technology) and Manu Bertrand (Business Developer Trasis)
Trasis SA与北京派特生物技术有限公司今日共同宣布，在中国正式成立合资企业，旨在进一步巩固并拓展双方在核医学领域逾十年的合作。新成立的合资公司将融合Trasis在放射性药物技术领域的尖端专长，与北京派特在中国医疗市场的深厚积淀及成熟的分销网络。Trasis在此合资公司中持有控股权。
北京派特首席执行官Jessie Yu（于静潇女士）阐释到：“中国正通过国家规划与投资，大力拓展核医学产业规模，目标是在2035年前实现三至四倍的增长。《医用同位素中长期发展规划》及‘健康中国2030’等政策，旨在将年度患者服务量提升至千万人次以上。我们坚信，与Trasis携手成立合资公司，并引入其市场领先的技术，是实现这一宏伟目标、造福中国民众健康的关键驱动力。”
Trasis首席执行官Gauthier Philippart表示：“我们非常高兴能够以更紧密的结构，延续与北京派特的长期合作。我们双方秉持共同的价值观——始终贴近用户，并立志站在核医学创新的最前沿。通过将本土市场布局与我们的放射性药物专业技术相结合，我们期望在一个清晰稳定的框架内，为中国市场提供可靠、高性能且高质量的解决方案。”
北京派特首席技术官Xiaoping Hu（胡晓平先生）强调：“北京派特与Trasis的合作已逾十年。此次合资将使我们的合作步入新阶段，并为在中国的长远发展提供一个坚实平台，同时确保为现有客户与合作伙伴提供持续稳定的服务。我们十分欣慰能进一步深化这段建立在信任、共同价值观及支持核医学发展一致抱负之上的伙伴关系。”
Trasis业务发展负责人Emmanuel Bertrand补充道：“我们成立合资公司的初衷，是为了让中国的医疗机构和患者能更便捷地获得先进的核医学解决方案。此举也深深植根于双方企业的共享价值观：通过服务贴近用户、追求技术卓越、以及强调团队精神与协作。合资公司将拓展我们的联合市场存在与增值服务，以更高效地响应中国医院、研究中心及放射性药物生产基地的需求。”
Trasis首席技术官Jean-Luc Morelle进一步表示：“对Trasis而言，这是一个绝佳的机遇，使我们能更贴近中国客户与患者，并推动技术进步与创新，最终惠及我们全球的客户。通过与北京派特开展更紧密的合作，我们能将双方对卓越与服务的共同承诺，转化为可在实地部署的具体解决方案。”
合资公司“创思派特生物技术（北京）有限公司”将采用 “Trasis Beijing” 作为其市场品牌。
根据计划，该项交易将于2026年初正式完成。此后，相关的资产与业务活动将在遵守相关法律法规和合同框架的前提下，自目前的运营实体“北京派特生物技术有限公司”分阶段过渡至新的合资公司法律实体。
在此次合资项目中，Trasis的法律顾问由VVR International与Leaf Legal担任，北京派特生物技术有限公司的法律顾问由方达律师事务所（Fangda Partners）担任。
【关于北京派特生物技术有限公司】
成立于2001年，总部位于北京，是一家专注于核医学领域的国家级高新技术企业。公司长期致力于放射性药物合成设备及耗材的研发与生产，自2014年起成为比利时TRASIS合成器中国独家代理商，在行业内建立了领先的市场地位。拥有多项专利与获奖创新成果，北京派特始终与医疗机构紧密合作，共同推动核医学的临床应用与科研发展，为中国精准医疗与核医学事业的高质量发展持续贡献力量。
【关于Trasis集团】
创立于2004年，已成为全球核医学领域的领先企业，专注于癌症与神经退行性疾病诊疗设备的研发与制造。全球每年有近2000万新发癌症病例，超过400万患者受益于Trasis创新、自动化的医疗技术。其业务遍及60多个国家，服务覆盖医院核医学科、研究中心及放射性药物企业，提供从放射药剂开发、生产到应用的全流程解决方案。2019至2024年间，Trasis年均增长率达31%，远高于行业10%的水平，2024年销售额达7200万欧元。集团在全球拥有约430名员工，超99%产品出口至国际市场。Trasis同时通过投资与孵化本土初创企业，积极支持生物技术与医疗科技生态建设，致力于推动核医学在全球范围内的治疗路径革新。
了解更多：www.trasis.com
立足新起点，携手新征程。TRASIS BEIJING将承载双方的理念与使命，为中国核医学发展注入全新动能。
联系人
北京派特生物技术有限公司
Jessie Yu （于静潇女士）, 首席执行官 (jessie.yu@petsv.com.cn)
Xiaoping Hu （胡晓平先生）, 首席技术官 (huxiaoping@petsv.com.cn)
Trasis SA
Laurie Brion, Communication Manager 传播经理 (brion@trasis.com)
Jacques Galloy, Administrator 管理层 (galloy@trasis.com)
Trasis and Beijing PET Technology strengthen long-term partnership with new joint venture to support nuclear medicine in China
Trasis SA and Beijing PET Technology Co. Ltd. announce the creation of a joint venture in China to further structure and expand their more than ten-year collaboration in the field of nuclear medicine. The new entity will combine Trasis’s expertise in radiopharmaceutical technologies with Beijing PET Technology’s experience in the Chinese healthcare market and established distribution network. Trasis holds a majority stake in the joint venture.
Jessie Yu, CEO of Beijing PET Technology, explained: “China is significantly expanding its nuclear medicine sector through government planning and investment, aiming to triple or even quadruple its size by 2035. The policies such as the "Mid-and Long-Term Development Plan for Medical Isotopes" and "Healthy China 2030" aim to increase patient services to over 10 million annually. We are convinced that the new joint venture with Trasis and its market leading technologies is a key driver in achieving this ambition and improving healthcare for the Chinese population”.
Gauthier Philippart, CEO of Trasis, stated : “We are happy to ensure a structured continuation of our long-standing collaboration with Beijing PET Technology. We share the same values of proximity with our users, and we want to be at the forefront of innovation in nuclear medicine. By combining local presence with our radiopharmaceutical expertise, we intend to provide the Chinese market with reliable, high performance and high-quality solutions within a clear and stable framework.”
Xiaoping Hu, CTO of Beijing PET Technology, commented: “Beijing PET Technology and Trasis have been working together for over a decade. The joint venture formalizes this collaboration and provides a solid platform for further development in China, while ensuring the continuity of our services for our existing customers and partners. We are delighted to deepen a partnership built on trust, shared values and a common ambition to support nuclear medicine.”
Emmanuel Bertrand, Business Developer of Trasis, said: “Our joint venture is designed to improve access to advanced nuclear medicine solutions for healthcare providers and patients in China. It is also rooted in the shared values of both companies: proximity to users through service, technical excellence, and a strong sense of team and collaboration. It will develop our joint presence and added value services to respond more efficiently to the needs of hospitals, research centers and radiopharmaceuticals manufacturing sites in China.”
Jean-Luc Morelle, CTO of Trasis, added: “This is a great opportunity for Trasis to get closer to Chinese customers and patients as well as to progress and innovate for the benefit of our customers worldwide. By working even more closely with Beijing PET Technology, we can translate our shared commitment to excellence and service into concrete solutions that can be deployed in the field.”
The joint venture Trasis PET Technology (Beijing) Co., Ltd will operate under the brand Trasis Beijing. As the deal closing is planned early 2026, the assets and business activities will be progressively transferred from current operating company “Beijing PET Technology Co. Ltd.” to the new legal entity, in line with the applicable legal and contractual framework.
Trasis has been advised by VVR International and Leaf Legal. Beijing PET Technology has been advised by Fangda Partners.
About Beijing PET
Founded in 2001 and headquartered in Beijing, China, Beijing PET Technology Co., Ltd. is a national high-tech enterprise specializing in the field of nuclear medicine. The company is dedicated to the R&D and production of radiopharmaceutical synthesis equipment and consumables. As the exclusive distributor in China for Belgium's TRASIS synthesizers since 2014, it has established a leading market presence in the sector. With multiple patents and award-winning innovations, Beijing PET collaborates closely with medical institutions to advance clinical applications and scientific research in nuclear medicine. Committed to supporting precision medicine, the company provides reliable technological solutions and continues to contribute to the high-quality development of China's nuclear medicine industry.
About Trasis
Founded in 2004, the Trasis group has grown into a global leader in nuclear medicine, specializing in the design and manufacture of advanced equipment and solutions for the diagnosis and treatment of cancer and neurodegenerative diseases. Every year, nearly 20 million new cancer cases are diagnosed worldwide, and over 4 million patients benefit from Trasis’ innovative, automated medical technologies that improve care quality while minimizing side effects. Operating in over 60 countries across hospital nuclear medicine departments, research centers, and radiopharmaceutical companies, Trasis provides integrated solutions spanning the development, production, and administration of radiotracers. Between 2019 and 2024, Trasis achieved an average annual growth rate of 31%, far outpacing the sector’s 10% growth, and reached €72 million in sales in 2024. With approximately 430 employees located in Belgium, France, the United States, China and beyond, more than 99% of its production is exported globally. Trasis also supports the biotech and medtech ecosystem by investing in and mentoring local start-ups, contributing to a future where nuclear medicine transforms therapeutic pathways for patients worldwide. Learn more at www.trasis.com.
Media contacts
Beijin PET Technology
Jessie Yu , CEO of Beijing PET Technology (jessie.yu@petsv.com.cn)
Xiaoping HU, CTO of Beijing PET Technology (huxiaoping@petsv.com.cn)
Trasis SA
Laurie Brion, Communication Manager (brion@trasis.com)
Jacques Galloy, Administrator (galloy@trasis.com)
